Retigabine or ezogabine is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. [2] The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline .

2020年7月2日 · The pharmacologic profile of retigabine [RTG (international nonproprietary name); ezogabine, EZG (U.S. adopted name)], is different from all currently approved antiepileptic drugs (AEDs). Its primary mechanism of action (MoA) as a positive allosteric modulator of KCNQ2-5 (K(v) 7.2-7.5) ion channels …

Retigabine is a commercial antiepileptic drug that increases currents through potassium channels, potentially reversing the effects of specific mutations associated with BFNE. You might find these chapters and articles relevant to this topic.

2011年9月30日 · Ezogabine is approved by the FDA for the adjunctive treatment of partial-onset seizures in patients aged 18 years and older 4. It is authorized by the European Commission for the adjunctive...

2012年1月5日 · Retigabine (RTG)/ezogabine (EZG) enhances magnitude and duration of KCNQ channel action to resist depolarization, and shifts voltage-dependence (VD) of KCNQ activation, leading to more rapid, prolonged, and increased levels of KCNQ channel opening in response to depolarizing stimuli.

2007年1月1日 · Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I …

Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results.

Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results.

Retigabine是一种新型的抗癫痫药，其机制主要是在神经元细胞中具有开放钾通道的活性。 Retigabine可显著地增强KCNQ2/Q3的电流。 除此之外，retigabine还可增强慢通道失活。

2012年8月29日 · Retigabine is indicated in the EU [8] and US [9] as an adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy. This article reviews the pharmacological, clinical efficacy and tolerability data relevant …